Therapeutic Agents
AssigneeAstraZeneca AB
InventorsJames R. Empfield, Michael Laplante, Megan Murphy King, Thomas R. Simpson, Maxime C. Tremblay, James M. Woods, Jingbo Yan
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Claims22
A compound of formula IA or pharmaceutically acceptable salts thereof
- wherein
- R1 and R2 are independently selected from hydrogen, —OH, halogen, C1-6alkyl, halogenated C1-6alkyl, C1-6alkoxy, halogenated C1-6alkoxy, —NR4C(═O)—O—R4, —S(═O)2—NR4R4 and —O—S(═O)2—R4;
- wherein each R4 is independently selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, and halogenated C3-6cycloalkyl;
- m and n are independently selected from 1, 2, 3, 4 and 5;
- X is selected from a bond, —C(═O)—, —S(═O)2—, —C(═O)—N—, and —C(═S)—N—;
- L is selected from a bond, —(CH2)p—, —(CH2)p—O—, —C(═O)—O—, —(CH2)pS—, —CH2NHC(═O)—CH2—,
- p is selected from 0, 1 and 2;
- R3 is selected from C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl, wherein said C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl are optionally substituted with one or more group selected from C1-6alkoxy, halogen, C1-6alkyl, halogenated C1-6alkyl, aryl, halogenated aryl, nitro, cyano, —C(═O)—R5, —CO2R5, —NHC(═O)—R5, wherein R5 is selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, halogenated C3-6cycloalkyl, heterocyclyl, benzhydryl and aryl, wherein said heterocyclyl, benzhydryl and aryl are optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a proviso that R3 is not unsubstituted phenyl;
- with a further proviso that at least one of X and L is not a bond;
- with another proviso that when both R1 and R2 are hydrogen, X is selected from —C(═O)— and —C(═O)—N—, and —C(═S)—N—;
- R3 is selected from propyl, aryl, heteroaryl and heterocycloalkyl substituted with one or more groups selected from R6—C(═O)—R6, and —NHC(═O)—R6, wherein R6 is selected from heterocyclyl, benzhydryl and aryl optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a further proviso that said compound is not one of:
- 1-[(3-tert-butyl-1-methyl-1h-pyrazol-5-yl)carbonyl]-4-[(3,4-dichlorophenyl)(phenyl)methyl]piperazine;
- and
- 1-(2,3-dihydro-1-benzofuran-5-ylcarbonyl)-4-(diphenylmethyl)piperazine.
A compound of formula IB or pharmaceutically acceptable salts thereof:
- wherein
- R1 and R2 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, trifluoromethyl, and methoxy;
- m and n are independently selected from 1 and 2;
- Ar1 is selected from phenyl, and C3-5heteroaryl, wherein said phenyl, and C3-5heteroaryl are substituted with one or more group selected from fluoro, chloro, bromo, nitro, methyl, trifluoromethyl, cyano, methoxy, and benzhydryl;
- and
- wherein at least one of R1 and R2 is not hydrogen.
A compound of formula IC or pharmaceutically acceptable salts thereof:
- wherein
- R1 and R2 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, trifluoromethyl, and methoxy;
- m and n are independently selected from 1 and 2;
- Ar1 is selected from phenyl, and C3-5heteroaryl, wherein said phenyl, and C3-5heteroaryl are substituted with one or more group selected from fluoro, chloro, bromo, nitro, methyl, trifluoromethyl, cyano, methoxy, and benzhydryl;
- and
- wherein at least one of R1 and R2 is not hydrogen.
A compound selected from one or more of the following:
- {4-[(4-Chlorophenyl)-phenyl-methyl]-piperazin-1-yl}-(3-fluorophenyl)-methanone;
- 1-Benzhydryl-3-(2-{4-[bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-2-oxoethyl)-imidazolidin-2-one;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(2-chloropyridin-3-yl)-methanone;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(4-fluorophenyl)-methanone;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(3-fluorophenyl)-methanone;
- 3-{4-[(4-Trifluoromethyl-phenyl)-phenyl-methyl]-piperazine-1-carbonyl}-benzonitrile;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(3-trifluoromethyl-phenyl)-methanone;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(2,5-difluorophenyl)-methanone;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(2-fluorophenyl)-methanone;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-cyclobutyl-methanone;
- 1-{4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-pentan-1-one;
- {4-[Bis-(4-chlorophenyl)-methyl]-piperazin-1-yl}-(3,5-ditrifluoromethyl-phenyl)-methanone;
- 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(5-methyl-2-thienyl)carbonyl]piperazine;
- 5-bromo-thiophen-2-yl)-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-methanone;
- and pharmaceutically acceptable salts thereof.
A compound of formula I or pharmaceutically acceptable salts thereof
- wherein
- G is selected from CH and N;
- R1 and R2 are independently selected from hydrogen, —OH, halogen, C1-6alkyl, halogenated C1-6alkyl, C1-6alkoxy, halogenated C1-6alkoxy, —NR4C(═O)—O—R4, —S(═O)2—NR4R4 and —O—S(═O)2—R4;
- wherein each R4 is independently selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, and halogenated C3-6cycloalkyl;
- m and n are independently selected from 1, 2, 3, 4 and 5;
- X is selected from a bond, —C(═O)—, —S(═O)2—, —C(═O)—N—, and —C(═S)—N—;
- L is selected from a bond, —(CH2)p—, —(CH2)p—O—, —C(═O)—O—, —(CH2)pS—, —CH2NHC(═O)—CH2—,
- p is selected from 0, 1 and 2;
- R3 is selected from C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl, wherein said C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl are optionally substituted with one or more group selected from C1-6alkoxy, halogen, C1-6alkyl, halogenated C1-6alkyl, aryl, halogenated aryl, nitro, cyano, —C(═O)—R5, —CO2R5, —NHC(═O)—R5, wherein R5 is selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, halogenated C3-6cycloalkyl, heterocyclyl, benzhydryl and aryl, wherein said heterocyclyl, benzhydryl and aryl are optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a proviso that R3 is not unsubstituted phenyl;
- with a further proviso that at least one of X and L is not a bond;
- with another proviso that when both R1 and R2 are hydrogen, X is selected from —C(═O)— and —C(═O)—N—, and —C(═S)—N—;
- R3 is selected from propyl, aryl, heteroaryl and heterocycloalkyl substituted with one or more groups selected from R6—C(═O)—R6, and —NHC(═O)—R6, wherein R6 is selected from heterocyclyl, benzhydryl and aryl optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a further proviso that said compound is not one of:
- 1-[(3-tert-butyl-1-methyl-1h-pyrazol-5-yl)carbonyl]-4-[(3,4-dichlorophenyl)(phenyl)methyl]piperazine;
- and
- 1-(2,3-dihydro-1-benzofuran-5-ylcarbonyl)-4-(diphenylmethyl)piperazine.
(canceled)
(canceled)
21-23. (canceled)
A process for the preparation of a compound of formula IA,
- comprising reacting a compound of formula II
- with Y—X-L-R3
- wherein
- Y represents a leaving group,
- R1 and R2 are independently selected from hydrogen, —OH, halogen, C1-6alkyl, halogenated C1-6alkyl, C1-6alkoxy, halogenated C1-6alkoxy, —NR4C(═O)—O—R4, —S(═O)2—NR4R4 and —O—S(═O)2—R4;
- wherein each R4 is independently selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, and halogenated C3-6cycloalkyl;
- m and n are independently selected from 1, 2, 3, 4 and 5;
- X is selected from a bond, —C(═O)—, —S(═O)2—, —C(═O)—N—, and —C(═S)—N—;
- L is selected from a bond, —(CH2)p—, —(CH2)p—O—, —C(═O)—O—, —(CH2)pS—, —CH2NHC(═O)—CH2—,
- p is selected from 0, 1 and 2;
- R3 is selected from C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl, wherein said C1-6alkyl, C3-6cycloalkyl, C6-10aryl, and C3-9heterocyclyl are optionally substituted with one or more group selected from C1-6alkoxy, halogen, C1-6alkyl, halogenated C1-6alkyl, aryl, halogenated aryl, nitro, cyano, —C(═O)—R5, —CO2R5, —NHC(═O)—R5, wherein R5 is selected from hydrogen, C1-6alkyl, halogenated C1-6alkyl, C3-6cycloalkyl, halogenated C3-6cycloalkyl, heterocyclyl, benzhydryl and aryl, wherein said heterocyclyl, benzhydryl and aryl are optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a proviso that R3 is not unsubstituted phenyl;
- with a further proviso that at least one of X and L is not a bond;
- with another proviso that when both R1 and R2 are hydrogen, X is selected from —C(═O)— and —C(═O)—N—, and —C(═S)—N—;
- R3 is selected from propyl, aryl, heteroaryl and heterocycloalkyl substituted with one or more groups selected from R6—C(═O)—R6, and —NHC(═O)—R6, wherein R6 is selected from heterocyclyl, benzhydryl and aryl optionally substituted by one or more group selected from halogen, C1-3alkyl, phenyl, and methoxy;
- with a further proviso that said compound is not one of:
- 1-[(3-tert-butyl-1-methyl-1h-pyrazol-5-yl)carbonyl]-4-[(3,4-dichlorophenyl)(phenyl)methyl]piperazine;
- and
- 1-(2,3-dihydro-1-benzofuran-5-ylcarbonyl)-4-(diphenylmethyl)piperazine.
Dependencies are inferred from the claim text.